Dr. Bennett Shapiro is a Partner of PureTech Ventures. He was most recently Executive Vice President, Worldwide Licensing and External Research for Merck. He joined Merck Research Laboratories in September 1990 as Executive Vice President, Basic Research, Merck Research Laboratories. In this position he was responsible for all the basic and preclinical research activities at Merck worldwide. Dr. Shapiro led the research program that resulted in FDA registration of approximately 20 drugs and vaccines -including Vioxx and Arcoxia (Cox 2 inhibitors) and Emend, going back as far as the A2 antagonist Cozaar, hepatitis A vaccine VACQTA, and many others.
